We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




First-of-Its-Kind Blood Test Could Transform Cancer Treatment

By LabMedica International staff writers
Posted on 21 Jul 2022
Print article
Image: Researchers aim to transform cancer treatment with just a tablespoon of blood (Photo courtesy of Pexels)
Image: Researchers aim to transform cancer treatment with just a tablespoon of blood (Photo courtesy of Pexels)

Metastatic cancer - cancer that has spread to other organs in the body - is not often curable, and chemotherapy and newer targeted therapies may not work for all patients. Biopsies to help determine the best treatments for this type of cancer are rarely performed due to their invasive nature and the high risk of complications. This is often a major barrier in studying and treating this disease. Now, a new blood test provides unprecedented insight into a patient’s cancer make-up, potentially allowing doctors to better select treatment options that will improve patient outcomes.

The first-of-its-kind blood test developed by researchers at the Vancouver Prostate Centre (British Columbia, Canada) and BC Cancer (British Columbia, Canada) analyzes the DNA that metastatic cancers shed into the bloodstream, known as circulating tumor DNA or ctDNA. By sequencing the entire genome of this ctDNA, the test reveals characteristics that are unique to each patient’s cancer, giving physicians new tools to develop more personalized treatment plans.

For their study, the researchers examined ctDNA samples collected from patients with metastatic prostate cancer. The researchers discovered that whole genome sequencing of ctDNA provides a host of information about the different metastases spread throughout the body. Using newly developed computer programs, the researchers were able to pinpoint the unique genetic make-up of various cancer populations in the body to gain a more comprehensive understanding of the disease. The researchers say the information can also be used to help predict which treatments will be effective or ineffective in each patient.

While the number of cancer treatment options has expanded in recent years, a common problem is that eventually those treatments stop working. Drug resistance can develop over time as cancer cells accumulate molecular changes that make them less sensitive to a particular drug or treatment. The study sheds new light on how this resistance develops. By collecting multiple ctDNA samples over time, the researchers were able to learn how cancer evolves in response to treatment. The findings revealed new genetic mechanisms of resistance to the most common drugs for treating metastatic prostate cancer and more broadly demonstrates how ctDNA profiling can be used to understand treatment resistance across other types of cancers. The researchers say that this minimally-invasive, relatively inexpensive and highly-scalable technology is now being deployed across large clinical trials.

“With only a few drops of blood, we can uncover critical information about a person’s overall disease and how best to manage their cancer,” said senior author Dr. Alexander Wyatt, an assistant professor of urologic sciences at the University of British Columbia (UBC) and senior research scientist at the Vancouver Prostate Centre. “This test has the potential to help clinicians choose better tailored treatment options and to more efficiently detect treatment resistance, allowing clinicians to adjust clinical care as needed.”

“Metastatic cancers are complex and our understanding of them has been limited. Whereas traditional biopsies only provide a small snapshot of the disease, this new test is able to paint a more complete picture of metastases throughout the body, all from a simple and easy to perform blood test,” added Dr. Wyatt. “Every cancer is unique and every patient responds differently to treatment. This new generation of ctDNA tests can help clinicians choose the treatment option that is most likely to benefit a patient.”

Related Links:
Vancouver Prostate Centre 
BC Cancer 

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
New
Gold Supplier
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
New
Gold Supplier
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Testicular Germ Cell Tumors Test
M371-Test

Print article
GLOBETECH PUBLISHING LLC

Channels

Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more

Hematology

view channel
Image: The latest FDA clearance has finally brought HemoScreen to its full potential as a true POC hematology analyzer (Photo courtesy of PixCell)

True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

An innovative 5-part differential Complete Blood Count (CBC) analyzer with direct capillary sampling capability significantly simplifies blood sampling and minimizes the pre-analytical process.... Read more

Immunology

view channel
Image: A new test could detect the body’s adaptive immune response to viruses (Photo courtesy of 123RF)

Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form

The adaptive immune system is an incredible defense mechanism that allows the human body to identify and mount targeted responses against specific pathogens. T-Cells, a special kind of white blood cell,... Read more

Microbiology

view channel
Image: On-chip pretreatment and rapid AST based directly on positive blood cultures (Photo courtesy of Liu Yang)

Integrated Solution for Rapid AST Directly From Positive Blood Cultures to Combat Bloodstream Infection

The presence of living bacteria in the bloodstream, known as bacteremia, can lead to serious conditions like bloodstream infections (BSIs) and sepsis, which can often be fatal. Quickly prescribing the... Read more

Pathology

view channel
Image: A new microscopy method detects treatment-resistant cancer cells early (Photo courtesy of 123RF)

New Rapid-Live Screening Microscopy Technique Enables Early Detection of Treatment-Resistant Cancer Cells

Chemotherapy serves as an effective tool in the fight against cancer, yet some cancer cells can evade treatment by going into a dormant state known as senescence. These so-called therapy-induced senescent... Read more

Technology

view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more

Industry

view channel
Image: AACC Middle East is a two-day conference that brings the latest in laboratory medicine to the Middle East region (Photo courtesy of ADLM)

AACC Middle East 2023 to Explore Latest Trends in Clinical Pathology and Laboratory Medicine

The AACC Middle East Conference and Exposition will be held by the Association for Diagnostics & Laboratory Medicine (ADLM - formerly AACC, Washington, DC, USA) in partnership with Life Dx (Abu Dhabi,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.